Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 2/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 8/20 | 0.36 |
| ▸ | CCR2 | P41597 | 5/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | CKS1B | P61024 | 1/20 | 0.33 |
| ▸ | SKP1 | P63208 | 1/20 | 0.33 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1959597 | 0.98 | CCR2 (0.36) | GCKPTGS2CCR2PTGS1NR1H2 | |
| SCHEMBL1960337 | 0.90 | GCK (0.33) | GCKCHRM3 | |
| SCHEMBL1959161 | 0.90 | GCK (0.33) | GCKCHRM3 | |
| SCHEMBL2054075 | 0.90 | NR3C2 (0.32) | GCKCHRM3 | |
| SCHEMBL1962132 | 0.89 | GCK (0.32) | GCKCHRM3 | |
| SCHEMBL1961245 | 0.89 | CHRM3 (0.33) | GCKCHRM3 | |
| SCHEMBL1961501 | 0.87 | GCK (0.45) | GCKPTGS2CCR2PTGS1NR1H2 | |
| SCHEMBL27889561 | 0.86 | FKBP1A (0.32) | CHRM3 | |
| SCHEMBL27873097 | 0.86 | NR1H3 (0.30) | CHRM3 | |
| SCHEMBL1960524 | 0.80 | GCK (0.41) | GCKCHRM3CKS1BSKP1SKP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2513103-A1 | AZAINDOLE GLUCOKINASE ACTIVATORS | F. Hoffmann-La Roche AG (CH) | 2012-10-24 | — | — | EP | disclosed |
| CN-102686587-A | Azaindole glucokinase activators | HOFFMANN LA ROCHE | 2012-09-19 | — | — | CN | disclosed |
| US-8222416-B2 | Azaindole glucokinase activators | HOFFMANN-LA ROCHE INC. (US) | 2012-07-17 | — | — | US | disclosed |
| WO-2011073117-A1 | AZAINDOLE GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-23 | — | — | WO | disclosed |
| US-20110144105-A1 | AZAINDOLE GLUCOKINASE ACTIVATORS | BERTHEL STEVEN JOSEPH | 2011-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144105-A1 | AZAINDOLE GLUCOKINASE ACTIVATORS | GCK, GCKR, GALK1 | GCK 1/4885PTGS2 1580/4885CCR2 4272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.